What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
Athira Pharma said on September 17, 2024, that it expected to eliminate approximately 49 positions—about 70% of its workforce—as part of a restructuring intended to reduce costs and focus resources on its ALS drug candidate ATH-1105. The figures were company estimates, not confirmation of the final number of departures or the savings ultimately achieved.
What Athira announced
Athira committed to the workforce reduction on September 15, 2024, according to its Form 8-K filed with the SEC. Two days later, the company announced the restructuring publicly. It estimated that approximately 49 positions would be terminated, representing about 70% of its workforce.
| # | Preview | Product | Price | |
|---|---|---|---|---|
| 1 |
|
Encyclopedia of Primary Prevention and Health Promotion | $199.99 | Buy on Amazon |
| 2 |
|
Textbook of Palliative Care | $844.44 | Buy on Amazon |
| 3 |
|
The Oxford Textbook of Clinical Research Ethics | $90.99 | Buy on Amazon |
| 4 |
|
Introduction to Research and Medical Literature for Health Professionals: . | $81.80 | Buy on Amazon |
| 5 |
|
Principles and Practice of Clinical Research | $78.72 | Buy on Amazon |
The filing describes positions expected to be terminated; it does not establish that exactly 49 employees ultimately left or specify the final timing of every departure. GeekWire also reported the approximately 49-person, 70% reduction in its September 17, 2024 coverage.
Why the company said it was restructuring
Athira said the cuts were intended to lower expenses, extend its cash runway and create a leaner organization aligned with its strategic priorities. The company identified continued development of ATH-1105 as a priority. Fierce Biotech likewise characterized the move as a pivot toward that ALS candidate after setbacks in the company’s Alzheimer’s program, fosgonimeton: Fierce Biotech’s report.
#1 Best Overall
The rationale links the immediate reduction in staffing with longer-term plans, but those are different kinds of effects: the headcount reduction and severance costs were near-term expectations, while savings and a longer runway were projections dependent on the company’s operating plan.
What Athira estimated about costs, savings and runway
| Item | Announcement-era estimate | How to interpret it |
|---|---|---|
| One-time restructuring costs | Approximately $2.8 million | Athira said these costs would consist primarily of cash severance and termination benefits and were expected to be recognized in the third quarter of 2024. The company cautioned that actual costs could differ materially and additional costs could arise. SEC filing |
| Annualized savings | Approximately $13.4 million | Athira’s September 2024 estimate, not a verified realized saving. Company release filed with the SEC |
| Cash runway | Into the first quarter of 2026 | Athira’s projection under its then-current operating plan, not confirmation of the company’s later cash position or actual runway. Company release filed with the SEC |
These estimates answer different questions. The $2.8 million was an expected one-time cost; the $13.4 million was an annualized savings estimate; and the runway statement was a forecast tied to Athira’s September 2024 plan. The company’s announcement does not independently establish the amount of savings realized or the cash runway ultimately achieved.
Rank #2
Leadership changes announced alongside the cuts
The SEC filing said Andrew Gengos, then chief business officer and chief financial officer, and Rachel Lenington, then chief operating officer and chief development officer, would depart effective October 1, 2024. Robert Renninger, then vice president of finance, was to become principal financial officer and principal accounting officer on that date. These were the leadership changes announced in connection with the restructuring.
How ATH-1105 fits into the plan
Athira described ATH-1105 as an oral, next-generation small-molecule positive modulator of the hepatocyte growth factor (HGF) system, in development for amyotrophic lateral sclerosis (ALS). In its September 2024 release, the company said the candidate was in a Phase 1 study in healthy volunteers and that it aimed to begin dosing ALS patients in 2025. Those statements describe the candidate and the company’s plan at that time; they do not establish safety or efficacy, and ATH-1105 was not an approved or commercially available medicine.
Rank #3
CEO Mark Litton said the company was encouraged by the candidate’s potential, describing it as having “enhanced blood-brain-barrier penetration and improved pharmacokinetic properties.” That was company commentary about a drug candidate, not an independent finding. Litton also thanked colleagues leaving in the restructuring and acknowledged their contributions to the company. Both statements appeared in Athira’s September 17, 2024 release.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.What is—and is not—established
The September 2024 SEC filing and company release establish what Athira announced and the estimates it made then. The cited coverage corroborates the reported scale and strategic context. These sources do not independently verify whether the reduction was completed on schedule, whether the projected savings were realized, or whether the runway projection was met. The figures should therefore be read as announcement-era estimates rather than confirmed outcomes.
Quick Recap
Best Value
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
